Summary of transactions
Over a three-day span in March 2026, a group of related investors, including OEP VII GP, L.L.C. and ONE EQUITY PARTNERS entities, reported purchases of AdaptHealth Corp. (NASDAQ:AHCO) common shares that totalled $19.9 million. Reported per-share prices for these purchases ranged narrowly from $9.7281 to $9.7299. The disclosed activity is concentrated in transactions executed on March 10, 11 and 12, with specific share totals and intraday price ranges for each date.
Detailed daily breakdown
- March 10: 820,528 shares purchased at prices between $9.58 and $9.95.
- March 11: 536,827 shares purchased at prices between $9.64 and $9.75.
- March 12: 689,336 shares purchased at prices between $9.55 and $9.75.
Together these trades sum to the reported $19.9 million in purchases executed across the three days. The consolidated reporting names associated with these transactions include OEP VII GP, L.L.C., OEP AHCO Investment Holdings, LLC, ONE EQUITY PARTNERS VII, L.P., ONE EQUITY PARTNERS VII-A, L.P., ONE EQUITY PARTNERS VII-B, L.P., OEP VII Project A Co-Investment Partners, L.P., OEP VII PROJECT A-I CO-INVESTMENT PARTNERS, L.P., OEP VII General Partner, L.P., and CASHIN RICHARD M JR.
Market context and valuation signals
At the time of reporting, AdaptHealth shares were trading at $11.29, close to a 52-week high of $11.75. Separately, InvestingPro analysis cited in the filings places a Fair Value for the company at $15.50, implying the stock was viewed as undervalued relative to that analytic conclusion.
Earnings release and analyst reactions
AdaptHealth’s fourth-quarter 2025 results, released in the period preceding these transactions, produced a significant miss on earnings per share while modestly topping revenue expectations. The company reported EPS of -$0.76 versus an expected $0.36, a negative surprise calculated at 311.11%. Revenue for the quarter was $846.3 million, ahead of the $832.5 million consensus forecast by 1.66%.
Investor response to the results showed some immediate optimism, as evidenced by a premarket uptick in the company’s stock following the announcement. At the same time, analysts weighed in with adjustments and reaffirmations. Leerink Partners lowered its price target to $12.00 from $13.00 but retained an Outperform rating. RBC Capital kept its Outperform rating and a $13.00 price target, noting a decline in the stock after the earnings release and the company’s guidance for 2026. Both firms commented on a mix of challenges and progress within AdaptHealth’s ongoing initiatives.
Coverage note
AdaptHealth is included among more than 1,400 U.S. equities covered by comprehensive Pro Research Reports referenced in the filings.
Conclusion
The three-day block of purchases reported by One Equity Partners-related entities and associated parties represents a concentrated acquisition of AdaptHealth common stock at prices in a narrow band just under $10 per share. These moves occurred amid a market backdrop of a sharp EPS miss, slight revenue outperformance for the fourth quarter of 2025, and mixed analyst messaging that adjusted price targets while maintaining constructive ratings.